**Name of Journal:** *World Journal of Psychiatry*

**Manuscript NO:** 90429

**Manuscript Type:** SYSTEMATIC REVIEWS

**Outcomes of long-acting injectable antipsychotics use in pregnancy: A literature review**

Pejčić AV *et al.* Long-acting injectable antipsychotics in pregnancy

Ana V Pejčić, Srdjan M Stefanović, Miloš N Milosavljević, Vladimir S Janjić, Marko M Folić, Nevena D Folić, Jovana Z Milosavljević

**Ana V Pejčić, Miloš N Milosavljević,** Department of Pharmacology and Toxicology, Faculty of Medical Sciences, University of Kragujevac, Kragujevac 34000, Serbia

**Srdjan M Stefanović, Marko M Folić,** Department of Pharmacy, Faculty of Medical Sciences, University of Kragujevac, Kragujevac 34000, Serbia

**Vladimir S Janjić,** Department of Psychiatry, Faculty of Medical Sciences, University of Kragujevac, Kragujevac 34000, Serbia

**Nevena D Folić,** Department of Pediatrics, Faculty of Medical Sciences, University of Kragujevac, Kragujevac 34000, Serbia

**Jovana Z Milosavljević,** Department of Anatomy, Faculty of Medical Sciences, University of Kragujevac, Kragujevac 34000, Serbia

**Author contributions:** Pejčić AV, Stefanović SM, Milosavljević MN, Janjić VS, Folić MM, Folić ND, and Milosavljević JZ contributed to conception, design, literature search, data analysis, drafting and editing of the manuscript, and approved the final manuscript.

**Corresponding author: Ana V Pejčić, PhD, Assistant Professor,** Department of Pharmacology and Toxicology, Faculty of Medical Sciences, University of Kragujevac, Svetozara Markovića 69, Kragujevac 34000, Serbia. anapejcic201502@yahoo.com

**Received:** December 3, 2023

**Revised:** February 5, 2024

**Accepted:** March 6, 2024

**Published online:**

**Abstract**

BACKGROUND

Women with a history of serious psychotic disorders are at increased risk of disease relapse during pregnancy. Long-acting injectable (LAI) antipsychotics have been widely used to improve adherence and prevent relapse in patients with various severe psychotic disorders, but there is a lack of high-quality data from previous research on the safety of LAI antipsychotics during pregnancy.

AIM

To summarize relevant data on maternal, pregnancy, neonatal, and developmental outcomes from published cases of LAI antipsychotic use in pregnancy.

METHODS

A literature search was performed through November 11, 2023, using three online databases: PubMed/MEDLINE, Scopus, and Web of Science. Case reports or case series that reported information about the outcomes of pregnancy in women who used LAI antipsychotics at any point in pregnancy, with available full texts, were included. Descriptive statistics, narrative summation, and tabulation of the extracted data were performed.

RESULTS

A total of 19 publications satisfied the inclusion criteria: 3 case series, 15 case reports, and 1 conference abstract. They reported the outcomes of LAI antipsychotic use in 74 women and 77 pregnancies. The use of second-generation LAI antipsychotics was reported in the majority (*n* = 47; 61.0%) of pregnancies. First-generation LAI antipsychotics were administered during 30 pregnancies (39.0%). Most of the women (approximately 64%) had either satisfactory control of symptoms or no information about relapse, while approximately 12% of them had developed gestational diabetes mellitus. A minority of cases reported adverse outcomes such as stillbirth, spontaneous abortion, preterm birth, low birth weight, congenital anomalies, and neurological manifestations in newborns. However, there were no reports of negative long-term developmental outcomes.

CONCLUSION

Currently available data seem reassuring, but further well-designed studies are required to properly evaluate the risks and benefits of LAI antipsychotic use during pregnancy.

**Key Words:** Antipsychotic agents; Long-acting injectable; Pregnancy; Outcome; Review

Pejčić AV, Stefanović SM, Milosavljević MN, Janjić VS, Folić MM, Folić ND, Milosavljević JZ. Outcomes of long-acting injectable antipsychotics use in pregnancy: A literature review. *World J Psychiatry* 2024; In press

**Core Tip:** Considering that the currently available research on the use of long-acting injectable antipsychotics in pregnancy consists only of case reports and series, additional well-designed studies are needed to properly evaluate the risks and benefits of their use during pregnancy. Currently available data seem reassuring, given that most of the women seemed to have satisfactory control of the symptoms and that a minority of the cases reported adverse outcomes, such as stillbirth, spontaneous abortion, preterm birth, low birth weight, congenital anomalies, and neurological manifestations in newborns, while there were no reported negative long-term developmental outcomes.

**INTRODUCTION**

Owing to their unique formulations, specific pharmacokinetic properties (*i.e.,* flip-flop kinetics), and accompanying innovations in drug delivery mechanisms, long-acting injectable (LAI) antipsychotics have been widely used in clinical practice for decades to improve adherence and prevent relapse, with the ultimate goal of reducing (re)hospitalization and mortality rates in patients with various severe psychotic disorders[1–3]. In fact, the use of these depot formulations with less frequent, more convenient dosing generally provides several relevant advantages over their oral counterparts[4–6]. By providing slow systemic absorption and continuous drug exposure with more stable blood levels, a potentially greater efficacy and acceptable safety profile are ensured, reflecting the previously mentioned beneficial effects on the main challenges regarding treatment outcomes of chronic diseases such as schizophrenia or bipolar disorder[1,7,8]. To date, several LAI antipsychotics have been approved[9,10], divided into first-generation or typical LAI antipsychotics (*e.g.,* haloperidol, fluphenazine, flupentixol, and zuclopenthixol) and second-generation or atypical LAI antipsychotics (*e.g.,* risperidone, olanzapine, aripiprazole, and paliperidone).

Women with a history of serious psychotic disorders are at increased risk of disease relapse during pregnancy, which can significantly endanger both the mother and the fetus, and satisfactory compliance with antipsychotic medications plays a key role in avoiding treatment failure[11–13]. Therefore, continuation and maintenance of antipsychotic therapy are necessary for pregnant women[14]. However, in daily clinical practice, antipsychotics are likely to be discontinued when pregnancy is confirmed for fear of possible teratogenicity or fetotoxicity[15,16]. Moreover, despite the current evidence showing that the use of oral antipsychotics is not significantly associated with poor pregnancy outcome[17,18], as well as a lack of high-quality data from previous research on the safety of LAI antipsychotics during pregnancy that does not clearly support their avoidance[19–21], it has been observed that psychiatrists prefer not to start or stop the use of LAI antipsychotics, even in pregnant women with an exceptionally high risk of psychotic symptom recurrence[22].

Apart from a significantly lower potential for overdose, LAI antipsychotics appear to share an overall safety profile similar to that of their oral counterparts[23,24]. An exception is the depot formulation of olanzapine[25], which requires strict monitoring for delirium or excessive sedation for a few hours immediately after intramuscular injection[26,27]. In addition, the women with pharmacokinetic changes reflected in the increased clearance of these drugs during pregnancy may require an increase in their doses[28]. Therefore, the decision to use and the choice of an appropriate LAI antipsychotic with an optimal benefit-risk ratio for an individual pregnant woman is challenging because numerous factors need to be considered, such as[29–31]: previous compliance to drug therapy (especially psychotropic drugs); use of antipsychotics/LAI antipsychotics in previous pregnancies if any, as well as the outcomes of such pregnancies; history of recurrent psychotic manifestations, especially if they led to long and frequent hospitalizations; history of licit or illicit abuse of psychoactive substances; compliance with the approved indication related to the psychotic or affective disorder; differences in the safety profile of individual LAI antipsychotics (*e.g.,* metabolic side effects among atypical antipsychotics); need for dose escalation and length of the dosing interval during pregnancy; and a pregnant woman's decision to breastfeed.

Previous reviews published several years ago identified 12 relevant case reports of both first- and second-generation LAI antipsychotic use during pregnancy[19] and 8 case reports/series of second-generation LAI antipsychotic use during pregnancy[32]. Considering that these reviews included only selected cases published before January and March 2021, respectively, and that several case reports/series reporting outcomes of pregnancy in women using LAI antipsychotics were published in the meantime[20,33,34] or were published earlier but not included in previous reviews[35], there is a need for an updated review. Therefore, our review aims to provide an up-to-date summary of the relevant data on maternal, pregnancy, neonatal, and developmental outcomes from available published cases of LAI antipsychotic use in pregnancy to help inform clinical decision-making. We also aimed to identify whether there are ongoing clinical studies assessing LAI antipsychotic use during pregnancy.

**MATERIALS AND METHODS**

Electronic literature searches were conducted using three online databases: PubMed/MEDLINE, Scopus, and Web of Science. A literature search was performed from the beginning of indexing until November 11, 2023, without language or date restrictions. A detailed search strategy for each database is presented in Table 1.

Case reports or case series that reported information about the outcomes of pregnancy in women who used LAI antipsychotics at any point in pregnancy, with available full texts, were included. LAI antipsychotics included first- (fluphenazine, haloperidol, zuclopenthixol, and flupentixol) and second-generation (aripiprazole, olanzapine, paliperidone, and risperidone) antipsychotics. Conference abstracts were included only if they contained sufficient data for analysis. Reviews, meta-analyses, commentaries, guidelines, “*in vitro*” studies, and animal studies were excluded. The eligibility of the retrieved publications was reviewed based on their titles and abstracts. When the title and information available in the abstract were insufficient for evaluating whether the publication properly corresponded to the research topic, we tried to retrieve and evaluate the full text. Publications were included that all the authors agreed met the eligibility criteria. Disagreements between the individual judgments were resolved by consensus.

Additionally, backward and forward citation searches were performed for publications that met the eligibility criteria. Backward citation searching was performed by inspecting the references cited in these publications, while forward citation searching was performed using the Google Scholar citation index on November 21, 2023, to identify publications that cited these publications.

We extracted the following data: type of publication, country, number of women, number of pregnancies, maternal age, information about alcohol/tobacco/illicit drug use during pregnancy, psychiatric diagnosis, information about LAI antipsychotic medication (name, dosage, and duration of treatment during pregnancy) and other medications used during pregnancy, maternal treatment outcomes (information about efficacy of LAI antipsychotic use and relapse of symptoms), gestational diabetes mellitus, pregnancy hypertension, premature rupture of membranes, delivery mode, live birth, stillbirth, spontaneous abortion, preterm birth, gestational age at birth, gender of the newborn, birth weight, Apgar score (at 1, 5, and 10 minutes), admission of the newborn to special care nursery or neonatal intensive care unit, neonatal and developmental outcomes, and main conclusions. Descriptive statistics, narrative summation, and tabulation of the extracted data were performed.

To identify ongoing clinical studies aimed at assessing the use of LAI antipsychotics during pregnancy, we searched the ClinicalTrials.gov database on January 23, 2024. We performed a search by entering previously mentioned LAI antipsychotics in the intervention/treatment search field, and pregnancy in the condition/disease search field.

**RESULTS**

***Results of the literature search***

Our search strategy identified 142 publications in PubMed/MEDLINE, 67 publications in Scopus, and 47 publications in Web of Science, and 200 total publications were screened for eligibility after duplicates were removed. Of these 200 publications, 17 met the inclusion criteria, and 183 were excluded (172 irrelevant publications, 6 review/consensus guidelines, 3 publications with unavailable full text, 1 conference abstract of an already included publication, and 1 conference abstract with incomplete data on pregnancy and delivery outcomes). We identified 2 additional publications via citation search; therefore, 19 publications satisfied the inclusion criteria: 3 case series[20,21,33], 15 case reports[34–48], and 1 conference abstract[49]. One case series reported aggregate data[20], while all others reported individual data.

***Main characteristics of included pregnant women***

An overview of the included publications/cases is presented in Table 2. They reported the outcomes of LAI antipsychotic use in 74 women and 77 pregnancies. The age of the pregnant women ranged from 20 to 43 years, and most were diagnosed with schizophrenia (*n* = 43; 58.1%), followed by schizoaffective disorder (*n* = 8; 10.8%), bipolar disorder (*n* = 5; 6.8%), and psychosis (*n* = 3; 4.0%). The exact diagnosis in 15 women (20.3%) reported by Eleftheriou *et al*[33] was not specified (either a bipolar or psychotic disorder). The majority of the women were from Australia (*n* = 39; 52.7%), followed by Italy (*n* = 15; 20.3%), Spain (*n* = 9; 12.2%), Turkey (*n* = 3; 4.0%), the United States (*n* = 3; 4.0%), Japan (*n* = 1; 1.3%), Portugal (*n* = 1; 1.3%), Serbia (*n* = 1; 1.3%), South Korea (*n* = 1; 1.3%), and Sweden (*n* = 1; 1.3%). Smoking, alcohol consumption, and the use of illicit drugs some point during pregnancy were reported in 33 (44.6%), 3 (4.0%), and 3 (4.0%) women, respectively.

***Characteristics of prescribed LAI antipsychotics***

In the majority (*n* = 47; 61.0%) of pregnancies, the use of second-generation LAI antipsychotics was reported [aripiprazole was used in 26 (33.8%); paliperidone in 14 (18.2%); risperidone in 6 (7.8%); and olanzapine in 1 (1.3%)]. First-generation LAI antipsychotics were used in 30 (39.0%) pregnancies [zuclopenthixol in 14 (18.2%); flupentixol in 9 (11.7%); fluphenazine in 5 (6.5%); and haloperidol in 2 (2.6%)]. The dosage and duration of LAI antipsychotic treatment during pregnancy varied considerably among individual medications, and this information is presented in Table 2. During more than half of the pregnancies, women reported using medications other than LAI antipsychotics (*n* = 46; 59.7%).

***Maternal outcomes***

Relapse/worsening of the patients’ condition during pregnancy, after delivery, and both during pregnancy and after delivery were reported in 15 (19.5%), 7 (9.1%), and 1 (1.3%) pregnancies, respectively. One patient (1.3%) required hospitalization for psychosis relapse after stillbirth, while another patient (1.3%) discontinued LAI antipsychotic use without consulting a clinician and was hospitalized for an acute psychotic attack. Improvement or partial control of symptoms was reported in 3 (3.9%) pregnancies. The remaining 49 (63.6%) had satisfactory symptom control or no information about relapse. Gestational diabetes mellitus was reported in nine (11.7%) pregnancies (two during the use of first-generation LAI antipsychotics and seven during the use of second-generation LAI antipsychotics). Elevated blood pressure during pregnancy was reported in 5 (6.5%) pregnancies (all were treated with first-generation LAI antipsychotics). One case series[20] reported that pregnant women treated with LAI antipsychotics were more likely to have obstetric complications, including gestational diabetes and pregnancy hypertension, than the general population. They also had elevated rates of psychiatric admission during pregnancy and statutory child protection involvement, while the outcomes were similar for first- and second-generation LAI antipsychotic exposures[20].

***Pregnancy and delivery outcomes***

Premature rupture of membranes was reported in six pregnancies (7.8%): four involved the use of first-generation LAI antipsychotics and two the use of second-generation LAI antipsychotics. The use of cesarean section as a delivery method was reported in 24 pregnancies (31.2%): 10 involved first-generation and 14 involved second-generation LAI antipsychotic use. One (1.3%) pregnancy ended in stillbirth, whereas two (2.6%) ended in spontaneous abortion (miscarriage), all of which involved the use of aripiprazole LAI. Preterm birth (< 37 wk) was reported in 11 (14.3%) pregnancies (6 and 5 involved first- and second-generation LAI use, respectively). The reported birth weight of babies ranged from 1800 to 3880 g, while 7 (9.5% of 74 live births) were specified as having a low birth weight (< 2500 g), all of whom were exposed to second-generation LAI antipsychotics (3 to aripiprazole, 2 to risperidone, and 2 to paliperidone). The average Apgar scores at 1, 5, and 10 min were 8.9, 9.7, and 9.8, respectively.

***Neonatal and developmental outcomes***

Admission to a special-care nursery or neonatal intensive care unit was reported in 21 babies (28.4% of 74 live births); 14 and 7 were exposed to first- and second-generation LAI antipsychotics, respectively. One case series[20] reported that pregnant women treated with LAI antipsychotics were more likely to have special care nursery admissions for their babies than the general population, while outcomes were similar for first- and second-generation LAI antipsychotic exposure[20].

Of the five babies who were exposed to fluphenazine LAI, one was born preterm in the 36th week with a normal karyotype but with multiple congenital anomalies (*e.g.,* bilateral cleft lip and palate, imperforate anus, and rectourethral fistula) requiring surgical interventions[36], while two experienced neurological manifestations at 3[37] and 4 wk[38] after delivery, but afterwards were doing well on follow-up. Neurological manifestations included possible minor extrapyramidal manifestations or withdrawal symptoms, which responded well to diphenhydramine, and this baby was apparently well developed at the 24-month follow-up[37], while the other baby developed symptoms consistent with withdrawal effects (*e.g.,* excessive irritability, choreiform and dystonic movements, jittery behavior, and hypertonicity), which persisted for 9 months and required treatment with diphenhydramine[38]. The baby did not show any abnormalities at the 15-month follow-up[38].

Of the two babies exposed to haloperidol LAI, one[39] developed possible tardive dyskinesia or withdrawal dyskinesia 8 days after birth, which continued until the 14th day of life and was successfully treated with clonazepam.

No significant anomalies or problems were reported in the 14 babies exposed to zuclopenthixol LAI[20,40]. Brain ultrasound revealed clinically insignificant periventricular hyperechogenicity in only one baby, but she was normally developed at the 3.5-year follow-up[40].

Of the nine babies exposed to flupentixol LAI, patent ductus arteriosus was reported only in one baby who was managed conservatively[20].

Of the 23 babies born alive who were exposed to aripiprazole LAI, one[21] experienced postural plagiocephaly and hypertonia during the first 6 wk of life that resolved with physiotherapy (he developed normally during the 3-year follow-up), one[21] remained in the incubator for 1 month due to prematurity (but developed normally during the 2-year follow-up), and one[33] was born preterm with Down’s syndrome, developed fetal hydrops complicated by septic shock and massive anuria, and died within 10 d (but this syndrome cannot be considered a drug-induced malformation).

One baby exposed to olanzapine LAI developed normally during the 3-year follow-up[42].

Of the 14 babies exposed to paliperidone LAI, one[34] experienced transient tachypnea that was managed with nasal continuous positive airway pressure (he developed normally during the 12-month follow-up), while another[46] was born with a minor correctable congenital anomaly, bilateral talipes equinovarus, which was managed conservatively (he was otherwise normal and the early postnatal course was uncomplicated). The average maternal plasma concentration of paliperidone in the latter case[46] was 13.8 ng/mL (15 h before delivery, 12.7 ng/mL; 9 h before delivery, 15.0 ng/mL), while the umbilical vein concentration was approximately half of the average maternal concentration (7.3 ng/mL), implying appreciable fetal exposure to the drug. However, it was also noted that the relationship between the baby's bilateral talipes equinovarus and paliperidone exposure is uncertain, considering that antipsychotic drug exposure in pregnancy has not been previously recognized as an association[46].

Of the six babies exposed to risperidone LAI, one[20] had undescended testes and was managed conservatively, while another[47] had intrauterine growth restriction and was born healthy but preterm with bilateral supernumerary nubs/digits on his hands that were removed after birth (this anomaly was a paternal family trait). This child met developmental milestones at 16 months[47].

***Ongoing clinical studies***

We identified only one currently recruiting study (“Long-acting Injectable Antipsychotics for Mental Ill-Health in Pregnancy and Postpartum” – NCT05766007) that specifically aims to assess safety and clinical outcomes of LAI antipsychotic use during pregnancy and postpartum[50]. This study also aims to determine the magnitude of changes in pharmacokinetics during pregnancy, assess the extent of fetal exposure at delivery, describe breastmilk pharmacokinetics of selected LAI antipsychotics, the extent of breastfed infant exposure, and the sources of variability in maternal and fetal/breastfed infant LAI antipsychotic exposure[50]. The study population includes pregnant and postpartum women aged at least 18 years receiving maintenance doses of LAI antipsychotics (risperidone, paliperidone palmitate, fluphenazine decanoate, flupenthixol decanoate, and zuclopenthixol decanoate)[50]. This observational prospective cohort study is being conducted in Nigeria and is sponsored by the University of Liverpool[50]. The study started on August 01, 2023 and is estimated to be completed in August 2025[50]. The estimated number of participants enrolled is 125[50]. We also found three currently recruiting studies that aim to evaluate outcomes of antipsychotic treatment during pregnancy, but these are not restricted to LAI antipsychotic use: “Maternal And Infant Antipsychotic Study” (NCT06049953)[51] being conducted in the United States since 2023, “National Pregnancy Registry for Psychiatric Medications” (NCT01246765)[52] being conducted in the United States since 2008, and “The National Register of Antipsychotic Medication in Pregnancy” (NCT00686946)[53] being conducted in Australia since 2005.

**DISCUSSION**

The currently available research on the use of LAI antipsychotics during pregnancy consists only of case reports and series, which are small and not generalizable. It is difficult to adequately interpret the data from these publications because many of the women who were evaluated had concurrent prescriptions for LAI and oral antipsychotics or other medications at some point throughout their pregnancy, and no control group was available for comparison. However, most of the women included in our review (about 64%) either had satisfactory control of the symptoms or no information about relapse, while about 12% had developed gestational diabetes mellitus (mostly on second-generation LAI antipsychotics). It is also important to note that a minority of cases reported adverse outcomes, such as stillbirth, spontaneous abortion, preterm birth, low birth weight, congenital anomalies, and neurological manifestations in newborns. Stillbirth and spontaneous abortion were reported only during the use of aripiprazole LAI, whereas low birth weight was reported only in newborns exposed to second-generation LAI antipsychotics. Preterm birth was reported with both first- and second-generation LAI antipsychotics. Neurological manifestations in newborns, including possible minor extrapyramidal manifestations, withdrawal symptoms, tardive dyskinesia, and withdrawal dyskinesia, were reported only for first-generation LAI (fluphenazine and haloperidol). Multiple congenital anomalies, such as bilateral cleft lip and palate, imperforate anus, and rectourethral fistula requiring surgical intervention, were reported in only one baby exposed to fluphenazine LAI. Other reported congenital anomalies were mostly managed conservatively. Only one neonate born preterm and exposed to aripiprazole LAI died 10 d after birth. However, the baby was born with Down’s syndrome, which cannot be considered a drug-induced malformation, and developed fetal hydrops, septic shock, and anuria. In addition, no negative long-term developmental outcomes following exposure to LAI antipsychotics during pregnancy were reported.

As previously noted, in terms of the use of LAI formulations in pregnancy as compared to that of oral formulations, there are currently no data in the literature that can be generalized; therefore, whether the risks of LAI antipsychotic use are the same, or more or less concerning, or if there are completely different risks involved compared to those of oral antipsychotics remains unclear[19,32]. However, more constant plasma drug levels associated with the use of LAI formulations may reduce fetal exposure to the highly fluctuating plasma drug levels associated with the use of oral formulations[32,54]. One case series[20] found that pregnant women treated with LAI antipsychotics were more likely to have obstetric complications and special care nursery admission for their babies compared to the general population, and outcomes were similar between first- and second-generation LAI antipsychotic exposure. Determining whether the outcomes are due to illness or medication factors (class of medication or long-acting formulations) remains an ongoing problem in this area[20]. In addition, some studies on the use of oral antipsychotics during pregnancy indicate a possible increased risk for complications like gestational diabetes[55–59], preterm birth[56,60–62], congenital malformations[63–65], withdrawal symptoms[66], and neonatal hospitalization[66–69]. Nevertheless, many of these findings have not been consistent across studies[60,62,70–75]. Furthermore, these studies are inherently confounded by indications as most have examined the use of medications during pregnancy[19,76]. It is also difficult to distinguish the effects of maternal illness from those of antipsychotic medications because there is documented evidence that the offspring of women with psychotic illness are highly likely to be at an increased risk of adverse outcomes due to higher rates of smoking, alcohol consumption, illicit substance use, maternal obesity, and reduced serum folate levels related to low dietary vitamin intake[77–80].

Another interesting observation in our review was that stillbirth and spontaneous abortion were only reported with the use of aripiprazole LAI. However, no causal relationship between these adverse pregnancy outcomes and the use of aripiprazole LAI could be established based on these data. One large nationwide cohort study found that women exposed to oral antipsychotics during pregnancy had a 34% higher risk of spontaneous abortion than unexposed women; however, the risk was similar to that in women exposed before (but not during) pregnancy[81]. In addition, the risk did not increase in exposed pregnancies compared with unexposed pregnancies in the same women[81]. Risk estimates were also rather similar for several types of antipsychotic medications, but the confidence intervals were wide, and the numbers were too small to perform adjusted analyses for most drugs[81]. Previous smaller studies did not find an increased risk of spontaneous abortion after prenatal exposure to atypical antipsychotics[82,83], therefore, the authors suggested that the overall higher risk of spontaneous abortion initially observed could be due to factors related to the underlying disease rather than antipsychotic medications[81]. In contrast, in the same study, the risk of stillbirth was twofold higher in pregnancies exposed to antipsychotics; however, owing to the small number of cases, they could not simultaneously adjust for multiple confounders[81]. A previous study found that the number of stillbirths was within the reference range (0 in 561 pregnant women exposed to second-generation antipsychotics and 2 in 284 pregnant women exposed to first-generation antipsychotics)[82].

Although most of the women included in our review (approximately 64%) either had satisfactory control of symptoms or no information about relapse, one case series[20] reported that pregnant women treated with LAI antipsychotics had elevated rates of psychiatric admissions during pregnancy and statutory child protection involvement, suggesting potential destabilization in the mental state associated with pregnancy or compounding psychosocial comorbidities[20].

For women on LAI antipsychotic treatment who become pregnant, it can be difficult to decide whether to continue with LAI or to switch to an oral form of the same antipsychotic, particularly considering that the discontinuation of antipsychotics during pregnancy is linked to an increased risk of bipolar and schizophrenia episode recurrence[84]. Each situation needs to be individually weighed on a case-by-case basis, and clinicians should plan, evaluate, and tailor treatment and management strategies during pregnancy, considering the patient's medical history, current treatment, and symptomatology[32]. Further well-designed research (*e.g.,* prospective longitudinal, observational, and database studies) is needed to properly evaluate the risks and benefits of continuing LAI *vs* switching to oral antipsychotics[19,32]. A shared large database, i.e., registers, for monitoring outcomes of mothers and their children over time could make significant progress in this area, and clinicians could incorporate planned longitudinal follow-up following discharge in their clinical practice to systematically collect all clinical variables of newborns exposed to LAI antipsychotics during pregnancy and the postpartum mental health status of women[32]. Our review identified only one ongoing observational prospective cohort clinical study conducted with the specific aim of assessing the safety and clinical outcomes of LAI antipsychotic use during pregnancy[50]. We hope that this study will provide further insights into the risks and benefits of LAI antipsychotic use during pregnancy.

**CONCLUSION**

Most of the women included in our review had either satisfactory symptom control or no information about relapse. A minority of the cases reported adverse outcomes, such as stillbirth, spontaneous abortion, preterm birth, low birth weight, congenital anomalies, and neurological manifestations in newborns, and there were no reported negative long-term developmental outcomes. Further well-designed studies are required to evaluate the risks and benefits of LAI antipsychotic use during pregnancy.

**ARTICLE HIGHLIGHTS**

***Research background***

Long-acting injectable (LAI) antipsychotics have been widely used to improve adherence and prevent relapse in patients with various severe psychotic disorders, but there is a lack of high-quality data from previous research on the safety of LAI antipsychotics during pregnancy.

***Research motivation***

Considering that previous reviews on this topic included only selected cases published before January and March 2021, respectively, and that several case reports/series reporting outcomes of pregnancy in women using LAI antipsychotics were published in the meantime or were published earlier but not included in previous reviews, there is a need for an updated review.

***Research objectives***

We aimed to provide an up-to-date summary of the relevant data on maternal, pregnancy, neonatal, and developmental outcomes from available published cases of LAI antipsychotic use in pregnancy.

***Research methods***

A literature search was performed through November 11, 2023, using three online databases: PubMed/MEDLINE, Scopus, and Web of Science. Case reports or case series that reported information about the outcomes of pregnancy in women who used LAI antipsychotics at any point in pregnancy, with available full texts, were included. Descriptive statistics, narrative summation, and tabulation of the extracted data were performed.

***Research results***

A total of 19 publications satisfied the inclusion criteria: 3 case series, 15 case reports, and 1 conference abstract. They reported the outcomes of LAI antipsychotic use in 74 women and 77 pregnancies. Most of the women (approximately 64%) had either satisfactory control of symptoms or no information about relapse. A minority of cases reported adverse outcomes such as stillbirth, spontaneous abortion, preterm birth, low birth weight, congenital anomalies, and neurological manifestations in newborns. However, there were no reports of negative long-term developmental outcomes.

Research conclusions

Currently available data seem reassuring, given that most of the women seemed to have satisfactory control of the symptoms and that a minority of the cases reported adverse outcomes.

Research perspectives

Considering that the currently available research consists only of case reports and series, additional well-designed studies are needed to properly evaluate the risks and benefits of LAI antipsychotic use during pregnancy.

**REFERENCES**

1 **Kishimoto T**, Hagi K, Nitta M, Leucht S, Olfson M, Kane JM, Correll CU. Effectiveness of Long-Acting Injectable *vs* Oral Antipsychotics in Patients With Schizophrenia: A Meta-analysis of Prospective and Retrospective Cohort Studies. *Schizophr Bull* 2018; **44**: 603-619 [PMID: 29868849 DOI: 10.1093/schbul/sbx090]

2 **Russu A**, Savitz A, Mathews M, Gopal S, Feng Y, Samtani MN. Pharmacokinetic-Pharmacodynamic Characterization of Relapse Risk for Paliperidone Palmitate 1-Month and 3-Month Formulations. *J Clin Psychopharmacol* 2019; **39**: 567-574 [PMID: 31688450 DOI: 10.1097/JCP.0000000000001137]

3 **Taipale H**, Mittendorfer-Rutz E, Alexanderson K, Majak M, Mehtälä J, Hoti F, Jedenius E, Enkusson D, Leval A, Sermon J, Tanskanen A, Tiihonen J. Antipsychotics and mortality in a nationwide cohort of 29,823 patients with schizophrenia. *Schizophr Res* 2018; **197**: 274-280 [PMID: 29274734 DOI: 10.1016/j.schres.2017.12.010]

4 **Kishimoto T**, Hagi K, Kurokawa S, Kane JM, Correll CU. Long-acting injectable versus oral antipsychotics for the maintenance treatment of schizophrenia: a systematic review and comparative meta-analysis of randomised, cohort, and pre-post studies. *Lancet Psychiatry* 2021; **8**: 387-404 [PMID: 33862018 DOI: 10.1016/S2215-0366(21)00039-0]

5 **Lin D**, Thompson-Leduc P, Ghelerter I, Nguyen H, Lafeuille MH, Benson C, Mavros P, Lefebvre P. Real-World Evidence of the Clinical and Economic Impact of Long-Acting Injectable Versus Oral Antipsychotics Among Patients with Schizophrenia in the United States: A Systematic Review and Meta-Analysis. *CNS Drugs* 2021; **35**: 469-481 [PMID: 33909272 DOI: 10.1007/s40263-021-00815-y]

6 **Toja-Camba FJ**, Gesto-Antelo N, Maroñas O, Echarri Arrieta E, Zarra-Ferro I, González-Barcia M, Bandín-Vilar E, Mangas Sanjuan V, Facal F, Arrojo Romero M, Carracedo A, Mondelo-García C, Fernández-Ferreiro A. Review of Pharmacokinetics and Pharmacogenetics in Atypical Long-Acting Injectable Antipsychotics. *Pharmaceutics* 2021; **13** [PMID: 34201784 DOI: 10.3390/pharmaceutics13070935]

7 **Misawa F**, Kishimoto T, Hagi K, Kane JM, Correll CU. Safety and tolerability of long-acting injectable versus oral antipsychotics: A meta-analysis of randomized controlled studies comparing the same antipsychotics. *Schizophr Res* 2016; **176**: 220-230 [PMID: 27499361 DOI: 10.1016/j.schres.2016.07.018]

8 **Ma N**, Zhang L, Zhang W, He Y, Ye C, Li X. Long-Acting Injectable Antipsychotic Treatment for Schizophrenia in Asian Population: A Scoping Review. *Neuropsychiatr Dis Treat* 2023; **19**: 1987-2006 [PMID: 37745189 DOI: 10.2147/NDT.S413371]

9 **Correll CU**, Kim E, Sliwa JK, Hamm W, Gopal S, Mathews M, Venkatasubramanian R, Saklad SR. Pharmacokinetic Characteristics of Long-Acting Injectable Antipsychotics for Schizophrenia: An Overview. *CNS Drugs* 2021; **35**: 39-59 [PMID: 33507525 DOI: 10.1007/s40263-020-00779-5]

10 **Lian L**, Kim DD, Procyshyn RM, Cázares D, Honer WG, Barr AM. Long-acting injectable antipsychotics for early psychosis: A comprehensive systematic review. *PLoS One* 2022; **17**: e0267808 [PMID: 35486616 DOI: 10.1371/journal.pone.0267808]

11 **Abdelhafez MA**, Ahmed KM, Ahmed NM, Ismail M, Mohd Daud MNB, Ping NPT, Eldiasty A, Amri MFB, Jeffree MS, Kadir F, Pg Baharuddin DM, Bolong MFB, Hayati F, BtAzizan N, Sumpat D, Syed Abdul Rahim SS, Abdel Malek EH. Psychiatric illness and pregnancy: A literature review. *Heliyon* 2023; **9**: e20958 [PMID: 37954333 DOI: 10.1016/j.heliyon.2023.e20958]

12 **Mohamed MA**, Elhelbawy A, Khalid M, AbdAllatif LA, Lialy HE. Effects of bipolar disorder on maternal and fetal health during pregnancy: a systematic review. *BMC Pregnancy Childbirth* 2023; **23**: 617 [PMID: 37641006 DOI: 10.1186/s12884-023-05924-8]

13 **Tang W**, Zhou LJ, Zhang WQ, Jia YJ, Hu FH, Chen HL. Adverse perinatal pregnancy outcomes in women with schizophrenia: A systematic review and meta-analysis. *Schizophr Res* 2023; **262**: 156-167 [PMID: 37979419 DOI: 10.1016/j.schres.2023.11.001]

14 **Edinoff AN**, Sathivadivel N, McNeil SE, Ly AI, Kweon J, Kelkar N, Cornett EM, Kaye AM, Kaye AD. Antipsychotic Use in Pregnancy: Patient Mental Health Challenges, Teratogenicity, Pregnancy Complications, and Postnatal Risks. *Neurol Int* 2022; **14**: 62-74 [PMID: 35076595 DOI: 10.3390/neurolint14010005]

15 **Petersen I**, McCrea RL, Osborn DJ, Evans S, Pinfold V, Cowen PJ, Gilbert R, Nazareth I. Discontinuation of antipsychotic medication in pregnancy: a cohort study. *Schizophr Res* 2014; **159**: 218-225 [PMID: 25171856 DOI: 10.1016/j.schres.2014.07.034]

16 **Park Y**, Huybrechts KF, Cohen JM, Bateman BT, Desai RJ, Patorno E, Mogun H, Cohen LS, Hernandez-Diaz S. Antipsychotic Medication Use Among Publicly Insured Pregnant Women in the United States. *Psychiatr Serv* 2017; **68**: 1112-1119 [PMID: 28617210 DOI: 10.1176/appi.ps.201600408]

17 **Cohen LS**, Viguera AC, McInerney KA, Freeman MP, Sosinsky AZ, Moustafa D, Marfurt SP, Kwiatkowski MA, Murphy SK, Farrell AM, Chitayat D, Hernández-Díaz S. Reproductive Safety of Second-Generation Antipsychotics: Current Data From the Massachusetts General Hospital National Pregnancy Registry for Atypical Antipsychotics. *Am J Psychiatry* 2016; **173**: 263-270 [PMID: 26441156 DOI: 10.1176/appi.ajp.2015.15040506]

18 **Slomski A**. Antipsychotic Use During Pregnancy Isn't Harmful to Children. *JAMA* 2021; **326**: 1666 [PMID: 34726717 DOI: 10.1001/jama.2021.19073]

19 **O'Sullivan DL**, Byatt N, Dossett EC. Long-Acting Injectable Antipsychotic Medications in Pregnancy: A Review. *J Acad Consult Liaison Psychiatry* 2022; **63**: 53-60 [PMID: 34461296 DOI: 10.1016/j.jaclp.2021.08.011]

20 **Nguyen T**, Frayne J, Watson S, Lebedevs T, Teoh S, Galbally M. Long-acting injectable antipsychotic treatment during pregnancy: Outcomes for women at a tertiary maternity hospital. *Psychiatry Res* 2022; **313**: 114614 [PMID: 35576628 DOI: 10.1016/j.psychres.2022.114614]

21 **Fernández-Abascal B**, Recio-Barbero M, Sáenz-Herrero M, Segarra R. Long-acting injectable aripiprazole in pregnant women with schizophrenia: a case-series report. *Ther Adv Psychopharmacol* 2021; **11**: 2045125321991277 [PMID: 35186259 DOI: 10.1177/2045125321991277]

22 **Brissos S**, Veguilla MR, Taylor D, Balanzá-Martinez V. The role of long-acting injectable antipsychotics in schizophrenia: a critical appraisal. *Ther Adv Psychopharmacol* 2014; **4**: 198-219 [PMID: 25360245 DOI: 10.1177/2045125314540297]

23 **Wang D**, Schneider-Thoma J, Siafis S, Burschinski A, Dong S, Wu H, Zhu Y, Davis JM, Priller J, Leucht S. Long-Acting Injectable Second-Generation Antipsychotics *vs* Placebo and Their Oral Formulations in Acute Schizophrenia: A Systematic Review and Meta-Analysis of Randomized-Controlled-Trials. *Schizophr Bull* 2024; **50**: 132-144 [PMID: 37350486 DOI: 10.1093/schbul/sbad089]

24 **Sathienluckana T**, Tiangpattanawong P, Chaiyasukthananoan K, Jittayanan P, Sawetwangsing H, Puchsaka P. Comparison of Efficacy and Safety between Long-Acting Injectable Antipsychotic Monotherapy and Combination of Long-Acting Injectable and Oral Antipsychotics in Patients with Schizophrenia. *Schizophr Res Treatment* 2021; **2021**: 8403986 [PMID: 34868682 DOI: 10.1155/2021/8403986]

25 **McDonnell DP**, Detke HC, Bergstrom RF, Kothare P, Johnson J, Stickelmeyer M, Sanchez-Felix MV, Sorsaburu S, Mitchell MI. Post-injection delirium/sedation syndrome in patients with schizophrenia treated with olanzapine long-acting injection, II: investigations of mechanism. *BMC Psychiatry* 2010; **10**: 45 [PMID: 20537130 DOI: 10.1186/1471-244X-10-45]

26 **Podgorná G**, Albrecht J, Buday J, Mareš T, Le TH, Kališová L, Anders M. Post-Injection Delirium/Sedation Syndrome: A Case Report and 2-Year Follow-Up. *Am J Case Rep* 2022; **23**: e937579 [PMID: 36245104 DOI: 10.12659/AJCR.937579]

27 **Torrico TJ**. The pathophysiology of rapid fluctuations in mental status associated with olanzapine: A case report. *Front Psychiatry* 2022; **13**: 1028350 [PMID: 37082516 DOI: 10.3389/fpsyt.2022.1028350]

28 **Westin AA**, Brekke M, Molden E, Skogvoll E, Castberg I, Spigset O. Treatment With Antipsychotics in Pregnancy: Changes in Drug Disposition. *Clin Pharmacol Ther* 2018; **103**: 477-484 [PMID: 28643331 DOI: 10.1002/cpt.770]

29 **Reinstein SA**, Cosgrove J, Malekshahi T, Deligiannidis KM. Long-Acting Injectable Antipsychotic Use During Pregnancy: A Brief Review and Concise Guide for Clinicians. *J Clin Psychiatry* 2020; **81** [PMID: 33238084 DOI: 10.4088/JCP.20ac13597]

30 **Raffi ER**, Nonacs R, Cohen LS. Safety of Psychotropic Medications During Pregnancy. *Clin Perinatol* 2019; **46**: 215-234 [PMID: 31010557 DOI: 10.1016/j.clp.2019.02.004]

31 **Dazzan P**. Schizophrenia during pregnancy. *Curr Opin Psychiatry* 2021; **34**: 238-244 [PMID: 33656465 DOI: 10.1097/YCO.0000000000000706]

32 **Orsolini L**, Sceusa F, Pompili S, Mauro A, Salvi V, Volpe U. Severe and persistent mental illness (SPMI) in pregnancy and breastfeeding: focus on second-generation long acting injectable antipsychotics. *Expert Opin Drug Saf* 2021; **20**: 1207-1224 [PMID: 33966552 DOI: 10.1080/14740338.2021.1928634]

33 **Eleftheriou G**, Butera R, Sangiovanni A, Palumbo C, Bondi E. Long-Acting Injectable Antipsychotic Treatment during Pregnancy: A Case Series. *Int J Environ Res Public Health* 2023; **20** [PMID: 36833772 DOI: 10.3390/ijerph20043080]

34 **Iwata Y**, Aruga Y, Ohtsuki M, Inoue M, Yasuda K, Hirata T, Uemura T, Suzuki T. Successful Introduction of Paliperidone Palmitate for Pregnant Woman With Schizophrenia: Case Presentation and Literature Review. *J Clin Psychopharmacol* 2021; **41**: 210-212 [PMID: 33666403 DOI: 10.1097/JCP.0000000000001338]

35 **Erdoğan E,** Delibas DH, Özcan S, Erdoğan İ, Sertoz ÖÖ. Maternal and newborn outcomes following paliperidone palmitate use during pregnancy and puerperal period in two women with schizophrenia. *Cukurova Med J* 2017; **42**: 758-762 [DOI: 10.17826/cumj.325991]

36 **Donaldson GL**, Bury RG. Multiple congenital abnormalities in a newborn boy associated with maternal use of fluphenazine enanthate and other drugs during pregnancy. *Acta Paediatr Scand* 1982; **71**: 335-338 [PMID: 7136644 DOI: 10.1111/j.1651-2227.1982.tb09428.x]

37 **Cleary MF**. Fluphenazine decanoate during pregnancy. *Am J Psychiatry* 1977; **134**: 815-816 [PMID: 869065 DOI: 10.1176/ajp.134.7.815]

38 **O'Connor M**, Johnson GH, James DI. Intrauterine effect of phenothiazines. *Med J Aust* 1981; **1**: 416-417 [PMID: 7254089 DOI: 10.5694/j.1326-5377.1981.tb135684.x]

39 **Collins KO**, Comer JB. Maternal haloperidol therapy associated with dyskinesia in a newborn. *Am J Health Syst Pharm* 2003; **60**: 2253-2255 [PMID: 14619120 DOI: 10.1093/ajhp/60.21.2253]

40 **Janjić V**, Milovanović DR, Zecević DR, Loncar D, Laban O, Stepanović M, Varjaric M, Obradović S, Dejanović SD, Janković S. Zuclopenthixol decanoate in pregnancy: successful outcomes in two consecutive offsprings of the same mother. *Vojnosanit Pregl* 2013; **70**: 526-529 [PMID: 23789295 DOI: 10.2298/vsp120208005j]

41 **Ballester-Gracia I**, Pérez-Almarcha M, Galvez-Llompart A, Hernandez-Viadel M. Use of long acting injectable aripiprazole before and through pregnancy in bipolar disorder: a case report. *BMC Pharmacol Toxicol* 2019; **20**: 52 [PMID: 31462311 DOI: 10.1186/s40360-019-0330-x]

42 **Manouilenko I**, Öhman I, Georgieva J. Long-acting olanzapine injection during pregnancy and breastfeeding: a case report. *Arch Womens Ment Health* 2018; **21**: 587-589 [PMID: 29637404 DOI: 10.1007/s00737-018-0840-3]

43 **de Azevedo Avelar R**, Luengo Corbal A, Heitor MJ. A case report of pregnancy and paliperidone palmitate 3-monthly long-acting injection. *Clin Case Rep* 2020; **8**: 2592-2594 [PMID: 33363785 DOI: 10.1002/ccr3.3213]

44 **Zamora Rodríguez FJ**, Benítez Vega C, Sánchez-Waisen Hernández MR, Guisado Macías JA, Vaz Leal FJ. Use of Paliperidone Palmitate Throughout a Schizoaffective Disorder Patient's Gestation Period. *Pharmacopsychiatry* 2017; **50**: 38-40 [PMID: 27414740 DOI: 10.1055/s-0042-110492]

45 **Özdemir AK**, Pak ŞC, Canan F, Geçici Ö, Kuloğlu M, Gücer MK. Paliperidone palmitate use in pregnancy in a woman with schizophrenia. *Arch Womens Ment Health* 2015; **18**: 739-740 [PMID: 25599999 DOI: 10.1007/s00737-014-0496-6]

46 **Binns R**, OʼHalloran SJ, Teoh S, Doherty K, Joyce DA. Placental Transfer of Paliperidone During Treatment With a Depot Formulation. *J Clin Psychopharmacol* 2017; **37**: 474-475 [PMID: 28486258 DOI: 10.1097/JCP.0000000000000714]

47 **Clinebell K**, Gannon J, Debrunner S, Roy Chengappa KN. Long-acting risperidone injections in a pregnant patient with bipolar disorder. *Bipolar Disord* 2017; **19**: 606-607 [PMID: 29120507 DOI: 10.1111/bdi.12572]

48 **Kim SW**, Kim KM, Kim JM, Shin IS, Shin HY, Yang SJ, Yoon JS. Use of long-acting injectable risperidone before and throughout pregnancy in schizophrenia. *Prog Neuropsychopharmacol Biol Psychiatry* 2007; **31**: 543-545 [PMID: 17110011 DOI: 10.1016/j.pnpbp.2006.09.017]

49 **Sole E,** Duran JI, Lera S, Torres A, Andres S, Garriga M, Garcia-Esteve L, Roca A. S206. Aripiprazole long-acting injectable in schizophrenia during pregnancy: a case report. *Schizophr Bull* 2020; **46**: S117 [DOI: 10.1093/schbul/sbaa031.272]

50 **University of Liverpool**. Long-acting injectable antipsychotics for mental ill-health in pregnancy and postpartum (LAMP). [accessed 2024 Jan 23] In: ClinicalTrials.gov [Internet]. Bethesda (MD): U.S. National Library of Medicine. Available from: https://clinicaltrials.gov/study/NCT05766007 ClinicalTrials.gov Identifier: NCT05766007

51 **Robakis T**. Maternal and infant antipsychotic study (MAIA). [accessed 2024 Jan 23] In: ClinicalTrials.gov [Internet]. Bethesda (MD): U.S. National Library of Medicine. Available from: https://clinicaltrials.gov/study/NCT06049953 ClinicalTrials.gov Identifier: NCT06049953

52 **Cohen LS**. National pregnancy registry for psychiatric medications. [accessed 2024 Jan 23] In: ClinicalTrials.gov [Internet]. Bethesda (MD): U.S. National Library of Medicine. Available from: https://clinicaltrials.gov/study/NCT01246765 ClinicalTrials.gov Identifier: NCT01246765

53 **Kulkarni J**. The national register of antipsychotic medication in pregnancy (NRAMP). [accessed 2024 Jan 23] In: ClinicalTrials.gov [Internet]. Bethesda (MD): U.S. National Library of Medicine. Available from: https://clinicaltrials.gov/study/NCT00686946 ClinicalTrials.gov Identifier: NCT00686946

54 **Ereshefsky L**, Mascarenas CA. Comparison of the effects of different routes of antipsychotic administration on pharmacokinetics and pharmacodynamics. *J Clin Psychiatry* 2003; **64 Suppl 16**: 18-23 [PMID: 14680415]

55 **Heinonen E**, Forsberg L, Nörby U, Wide K, Källén K. Antipsychotic Use During Pregnancy and Risk for Gestational Diabetes: A National Register-Based Cohort Study in Sweden. *CNS Drugs* 2022; **36**: 529-539 [PMID: 35220525 DOI: 10.1007/s40263-022-00908-2]

56 **Ellfolk M**, Leinonen MK, Gissler M, Lahesmaa-Korpinen AM, Saastamoinen L, Nurminen ML, Malm H. Second-generation antipsychotics and pregnancy complications. *Eur J Clin Pharmacol* 2020; **76**: 107-115 [PMID: 31680189 DOI: 10.1007/s00228-019-02769-z]

57 **Wang Z**, Wong ICK, Man KKC, Alfageh BH, Mongkhon P, Brauer R. The use of antipsychotic agents during pregnancy and the risk of gestational diabetes mellitus: a systematic review and meta-analysis. *Psychol Med* 2021; **51**: 1028-1037 [PMID: 31969198 DOI: 10.1017/S003329171900401X]

58 **Galbally M**, Frayne J, Watson SJ, Morgan V, Snellen M. The association between gestational diabetes mellitus, antipsychotics and severe mental illness in pregnancy: A multicentre study. *Aust N Z J Obstet Gynaecol* 2020; **60**: 63-69 [PMID: 31141172 DOI: 10.1111/ajo.12986]

59 **Park Y**, Hernandez-Diaz S, Bateman BT, Cohen JM, Desai RJ, Patorno E, Glynn RJ, Cohen LS, Mogun H, Huybrechts KF. Continuation of Atypical Antipsychotic Medication During Early Pregnancy and the Risk of Gestational Diabetes. *Am J Psychiatry* 2018; **175**: 564-574 [PMID: 29730938 DOI: 10.1176/appi.ajp.2018.17040393]

60 **Lin HY**, Lin FJ, Katz AJ, Wang IT, Wu CH. Antipsychotic Use in Early Pregnancy and the Risk of Maternal and Neonatal Complications. *Mayo Clin Proc* 2022; **97**: 2086-2096 [PMID: 36210203 DOI: 10.1016/j.mayocp.2022.04.006]

61 **Andrade C**. Gestational and Neurodevelopmental Outcomes Associated With Antipsychotic Drug Exposure During Pregnancy. *J Clin Psychiatry* 2021; **82** [PMID: 34644464 DOI: 10.4088/JCP.21f14265]

62 **Lin HC**, Chen IJ, Chen YH, Lee HC, Wu FJ. Maternal schizophrenia and pregnancy outcome: does the use of antipsychotics make a difference? *Schizophr Res* 2010; **116**: 55-60 [PMID: 19896335 DOI: 10.1016/j.schres.2009.10.011]

63 **Huybrechts KF**, Straub L, Karlsson P, Pazzagli L, Furu K, Gissler M, Hernandez-Diaz S, Nørgaard M, Zoega H, Bateman BT, Cesta CE, Cohen JM, Leinonen MK, Reutfors J, Selmer RM, Suarez EA, Ulrichsen SP, Kieler H. Association of In Utero Antipsychotic Medication Exposure With Risk of Congenital Malformations in Nordic Countries and the US. *JAMA Psychiatry* 2023; **80**: 156-166 [PMID: 36477338 DOI: 10.1001/jamapsychiatry.2022.4109]

64 **Ellfolk M**, Leinonen MK, Gissler M, Kiuru-Kuhlefelt S, Saastamoinen L, Malm H. Second-generation antipsychotic use during pregnancy and risk of congenital malformations. *Eur J Clin Pharmacol* 2021; **77**: 1737-1745 [PMID: 34100993 DOI: 10.1007/s00228-021-03169-y]

65 **Anderson KN**, Ailes EC, Lind JN, Broussard CS, Bitsko RH, Friedman JM, Bobo WV, Reefhuis J, Tinker SC; National Birth Defects Prevention Study. Atypical antipsychotic use during pregnancy and birth defect risk: National Birth Defects Prevention Study, 1997-2011. *Schizophr Res* 2020; **215**: 81-88 [PMID: 31761471 DOI: 10.1016/j.schres.2019.11.019]

66 **Heinonen E**, Forsberg L, Nörby U, Wide K, Källén K. Neonatal morbidity after fetal exposure to antipsychotics: a national register-based study. *BMJ Open* 2022; **12**: e061328 [PMID: 35768086 DOI: 10.1136/bmjopen-2022-061328]

67 **Sadowski A**, Todorow M, Yazdani Brojeni P, Koren G, Nulman I. Pregnancy outcomes following maternal exposure to second-generation antipsychotics given with other psychotropic drugs: a cohort study. *BMJ Open* 2013; **3** [PMID: 23852139 DOI: 10.1136/bmjopen-2013-003062]

68 **Kulkarni J**, Worsley R, Gilbert H, Gavrilidis E, Van Rheenen TE, Wang W, McCauley K, Fitzgerald P. A prospective cohort study of antipsychotic medications in pregnancy: the first 147 pregnancies and 100 one year old babies. *PLoS One* 2014; **9**: e94788 [PMID: 24787688 DOI: 10.1371/journal.pone.0094788]

69 **Kulkarni J**, Worsley R, Gilbert H, Gavrilidis E, Van Rheenen TE, Wang W, McCauley K, Fitzgerald P. Correction: A Prospective Cohort Study of Antipsychotic Medications in Pregnancy: The First 147 Pregnancies and 100 One Year Old Babies. *PLoS One* 2023; **18**: e0290614 [PMID: 37624837 DOI: 10.1371/journal.pone.0290614]

70 **Wang Z**, Chan AYL, Coghill D, Ip P, Lau WCY, Simonoff E, Brauer R, Wei L, Wong ICK, Man KKC. Association Between Prenatal Exposure to Antipsychotics and Attention-Deficit/Hyperactivity Disorder, Autism Spectrum Disorder, Preterm Birth, and Small for Gestational Age. *JAMA Intern Med* 2021; **181**: 1332-1340 [PMID: 34398171 DOI: 10.1001/jamainternmed.2021.4571]

71 **Huybrechts KF**, Hernández-Díaz S, Patorno E, Desai RJ, Mogun H, Dejene SZ, Cohen JM, Panchaud A, Cohen L, Bateman BT. Antipsychotic Use in Pregnancy and the Risk for Congenital Malformations. *JAMA Psychiatry* 2016; **73**: 938-946 [PMID: 27540849 DOI: 10.1001/jamapsychiatry.2016.1520]

72 **Vigod SN**, Gomes T, Wilton AS, Taylor VH, Ray JG. Antipsychotic drug use in pregnancy: high dimensional, propensity matched, population based cohort study. *BMJ* 2015; **350**: h2298 [PMID: 25972273 DOI: 10.1136/bmj.h2298]

73 **Wang Z**, Man KKC, Ma T, Howard LM, Wei L, Wong ICK, Brauer R. Association between antipsychotic use in pregnancy and the risk of gestational diabetes: Population-based cohort studies from the United Kingdom and Hong Kong and an updated meta-analysis. *Schizophr Res* 2021; **229**: 55-62 [PMID: 33243714 DOI: 10.1016/j.schres.2020.11.021]

74 **Viguera AC**, Freeman MP, Kobylski LA, Rossa ET, Gaccione P, Chitayat D, Hernández-Díaz S, Cohen LS. Risk of Major Malformations Following First-Trimester Exposure to Olanzapine: Preliminary Data From the Massachusetts General Hospital National Pregnancy Registry for Psychiatric Medications. *J Clin Psychopharmacol* 2023; **43**: 106-112 [PMID: 36825887 DOI: 10.1097/JCP.0000000000001665]

75 **Cohen LS**, Góez-Mogollón L, Sosinsky AZ, Savella GM, Viguera AC, Chitayat D, Hernández-Díaz S, Freeman MP. Risk of Major Malformations in Infants Following First-Trimester Exposure to Quetiapine. *Am J Psychiatry* 2018; **175**: 1225-1231 [PMID: 30111186 DOI: 10.1176/appi.ajp.2018.18010098]

76 **Källén B**. The problem of confounding in studies of the effect of maternal drug use on pregnancy outcome. *Obstet Gynecol Int* 2012; **2012**: 148616 [PMID: 22190949 DOI: 10.1155/2012/148616]

77 **Abel KM**. Fetal antipsychotic exposure in a changing landscape: seeing the future. *Br J Psychiatry* 2013; **202**: 321-323 [PMID: 23637105 DOI: 10.1192/bjp.bp.112.117556]

78 **Zhong QY**, Gelaye B, Fricchione GL, Avillach P, Karlson EW, Williams MA. Adverse obstetric and neonatal outcomes complicated by psychosis among pregnant women in the United States. *BMC Pregnancy Childbirth* 2018; **18**: 120 [PMID: 29720114 DOI: 10.1186/s12884-018-1750-0]

79 **Nilsson E**, Hultman CM, Cnattingius S, Olausson PO, Björk C, Lichtenstein P. Schizophrenia and offspring's risk for adverse pregnancy outcomes and infant death. *Br J Psychiatry* 2008; **193**: 311-315 [PMID: 18827293 DOI: 10.1192/bjp.bp.107.045146]

80 **Vigod SN**, Fung K, Amartey A, Bartsch E, Felemban R, Saunders N, Guttmann A, Chiu M, Barker LC, Kurdyak P, Brown HK. Maternal schizophrenia and adverse birth outcomes: what mediates the risk? *Soc Psychiatry Psychiatr Epidemiol* 2020; **55**: 561-570 [PMID: 31811316 DOI: 10.1007/s00127-019-01814-7]

81 **Sørensen MJ**, Kjaersgaard MI, Pedersen HS, Vestergaard M, Christensen J, Olsen J, Parner E, Pedersen LH, Bech BH. Risk of Fetal Death after Treatment with Antipsychotic Medications during Pregnancy. *PLoS One* 2015; **10**: e0132280 [PMID: 26162087 DOI: 10.1371/journal.pone.0132280]

82 **Habermann F**, Fritzsche J, Fuhlbrück F, Wacker E, Allignol A, Weber-Schoendorfer C, Meister R, Schaefer C. Atypical antipsychotic drugs and pregnancy outcome: a prospective, cohort study. *J Clin Psychopharmacol* 2013; **33**: 453-462 [PMID: 23764684 DOI: 10.1097/JCP.0b013e318295fe12]

83 **McKenna K**, Koren G, Tetelbaum M, Wilton L, Shakir S, Diav-Citrin O, Levinson A, Zipursky RB, Einarson A. Pregnancy outcome of women using atypical antipsychotic drugs: a prospective comparative study. *J Clin Psychiatry* 2005; **66**: 444-9; quiz 546 [PMID: 15816786 DOI: 10.4088/jcp.v66n0406]

84 **Betcher HK**, Montiel C, Clark CT. Use of Antipsychotic Drugs During Pregnancy. *Curr Treat Options Psychiatry* 2019; **6**: 17-31 [PMID: 32775146 DOI: 10.1007/s40501-019-0165-5]

**Footnotes**

**Conflict-of-interest statement:** Authors declare no conflict of interests for this article.

**PRISMA 2009 Checklist statement:** The authors have read the PRISMA 2009 Checklist, and the manuscript was prepared and revised according to the PRISMA 2009 Checklist.

**Open-Access:** This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: https://creativecommons.org/Licenses/by-nc/4.0/

**Provenance and peer review:** Invited article; Externally peer reviewed.

**Peer-review model:** Single blind

**Peer-review started:** December 3, 2023

**First decision:** January 23, 2024

**Article in press:**

**Specialty type:** Psychiatry

**Country/Territory of origin:** Serbia

**Peer-review report’s scientific quality classification**

Grade A (Excellent): 0

Grade B (Very good): 0

Grade C (Good): C

Grade D (Fair): 0

Grade E (Poor): 0

**P-Reviewer:** Zhao Y, China **S-Editor:** Lin C **L-Editor:** A **P-Editor:**

**Table 1 A detailed search strategy for each database**

|  |  |
| --- | --- |
| Database | Search strategy |
| PubMed/MEDLINE | (("antipsychotic agents” [Pharmacological Action] OR "antipsychotic agents” [MeSH Terms] OR ("antipsychotic” [All Fields] AND "agents” [All Fields]) OR "antipsychotic agents” [All Fields] OR "antipsychotic” [All Fields] OR "antipsychotics” [All Fields] OR "antipsychotics” [All Fields] OR "antipsychotically” [All Fields] OR ("antipsychotic agents” [Pharmacological Action] OR "antipsychotic agents” [MeSH Terms] OR ("antipsychotic” [All Fields] AND "agents” [All Fields]) OR "antipsychotic agents” [All Fields] OR "antipsychotic” [All Fields] OR "antipsychotics” [All Fields] OR "antipsychotic s” [All Fields] OR "antipsychotically” [All Fields]) OR ("antipsychotic agents” [Pharmacological Action] OR "antipsychotic agents” [MeSH Terms] OR ("antipsychotic” [All Fields] AND "agents” [All Fields]) OR "antipsychotic agents” [All Fields] OR "neuroleptic” [All Fields] OR "neuroleptics” [All Fields] OR "neuroleptical” [All Fields] OR "neuroleptically” [All Fields] OR "neuroleptization” [All Fields]) OR ("antipsychotic agents” [Pharmacological Action] OR "antipsychotic agents” [MeSH Terms] OR ("antipsychotic” [All Fields] AND "agents” [All Fields]) OR "antipsychotic agents” [All Fields] OR "neuroleptic” [All Fields] OR "neuroleptics” [All Fields] OR "neuroleptical” [All Fields] OR "neuroleptically” [All Fields] OR "neuroleptization” [All Fields]) OR ("aripiprazole” [MeSH Terms] OR "aripiprazole” [All Fields] OR "aripiprazol” [All Fields] OR "aripiprazole s” [All Fields]) OR ("fluphenazine” [MeSH Terms] OR "fluphenazine” [All Fields]) OR ("haloperidol” [MeSH Terms] OR "haloperidol” [All Fields] OR "haloperidol s” [All Fields] OR "haloperidole” [All Fields]) OR ("flupenthixol” [MeSH Terms] OR "flupenthixol” [All Fields] OR "flupentixol” [All Fields]) OR ("clopenthixol” [MeSH Terms] OR "clopenthixol” [All Fields] OR "zuclopenthixol” [All Fields]) OR ("olanzapine” [MeSH Terms] OR "olanzapine” [All Fields] OR "olanzapin” [All Fields] OR "olanzapine s” [All Fields]) OR ("paliperidone palmitate” [MeSH Terms] OR ("paliperidone” [All Fields] AND "palmitate” [All Fields]) OR "paliperidone palmitate” [All Fields] OR "paliperidone” [All Fields] OR "paliperidone s” [All Fields]) OR ("risperidon” [All Fields] OR "risperidone” [MeSH Terms] OR "risperidone” [All Fields] OR "risperidone s” [All Fields])) AND ("long-acting” [All Fields] OR ("inject” [All Fields] OR "injectability” [All Fields] OR "injectant” [All Fields] OR "injectants” [All Fields] OR "injectate” [All Fields] OR "injectates” [All Fields] OR "injected” [All Fields] OR "injectible” [All Fields] OR "injectibles” [All Fields] OR "injecting” [All Fields] OR "injections” [MeSH Terms] OR "injections” [All Fields] OR "injectable” [All Fields] OR "injectables” [All Fields] OR "injection” [All Fields] OR "injects” [All Fields]) OR ("depot” [All Fields] OR "depots” [All Fields])) AND ("pregnancy” [MeSH Terms] OR "pregnancy” [All Fields] OR "pregnancies” [All Fields] OR "pregnancy s” [All Fields] OR ("pregnant” [All Fields] OR "pregnants” [All Fields]))) NOT ("mice” [MeSH Terms] OR "mice” [All Fields] OR "mouse” [All Fields] OR "mouse s” [All Fields] OR "mouses” [All Fields] OR ("mice” [MeSH Terms] OR "mice” [All Fields]) OR ("rats” [MeSH Terms] OR "rats” [All Fields] OR "rat” [All Fields])) |
| Web of Science | In all databases and all collections (Web of Science Core Collection; KCI-Korean Journal Database; Preprint Citation Index; ProQuest™ Dissertations & Theses Citation Index; SciELO Citation Index): TS = (antipsychotic OR antipsychotics OR neuroleptic OR neuroleptics OR aripiprazole OR fluphenazine OR haloperidol OR flupenthixol OR flupentixol OR zuclopenthixol OR olanzapine OR paliperidone OR risperidone) AND TS = (long-acting OR injectable OR depot) AND TS = (pregnancy OR pregnant) |
| Scopus | TITLE-ABS-KEY ((antipsychotic OR antipsychotics OR neuroleptic OR neuroleptics OR aripiprazole OR fluphenazine OR haloperidol OR flupenthixol OR flupentixol OR zuclopenthixol OR olanzapine OR paliperidone OR risperidone) AND (long-acting OR injectable OR depot) AND (pregnancy OR pregnant)) |

**Table 2 An overview of included publications/cases**

|  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- |
| No. | Ref. | Maternal age (yr) | Type of publication, No. of women/pregnancies | Psychiatric diagnosis | LAI-AP medication (dosage, duration of treatment during pregnancy); other medications used during pregnancy | Maternal treatment outcomes | Pregnancy and delivery outcomes (gestational age, gender, birth weight, Apgar score 1/5/10 min) | Neonatal and developmental outcomes |
| 1 | Donaldson and Bury[36], 1982 | 29 | Case report, 1/1 | Hebephrenic schizophrenia | Fluphenazine enanthate(25 mg/month, entire pregnancy); dicyclomine hydrochloride, doxylamine succinate and pyridoxine hydrochloride (from 45 to 101 d of gestation), ferrous sulphate, folic acid (from day 101 to near delivery), paracetamol (from day 165 to near delivery), sodium amytal (from day 250 to 255) | Her symptoms improved during pregnancy | Labor was induced surgically and proceeded to forceps delivery (36 wk, male, 2520 g, 9/NR/NR) | Born with a short sloping forehead, wide metopic suture, persistent metopic fontanelle, telecanthus, ocular hypertelorism, nystagmoid eye movements, bilateral cleft lip and palate, imperforate anus, rectourethral fistula, bifid scrotum, unusual penis with hypospadias, and neutrophil polymorphs with numerous nuclear projections. His overall progress was good, with the rectourethral fistula divided and anoplasty performed soon after delivery and the cleft lip and palate repaired at 7 months |
| 2 | Cleary[37], 1977 | 32 | Case report, 1/1 | Schizophrenia | Fluphenazine decanoate(2 cc every 3 wk, entire pregnancy); benztropine mesylate sporadically | Latent homicidal ideas were noted late in pregnancy, and her behavior continued to be bizarre, explosive, and unpredictable. Two months after delivery, she developed somatic delusions, became agitated and paranoid, and was readmitted to a psychiatric hospital. After discharge and some months later, she indicated the persistence of a schizophrenic thought disorder | Delivered by cesarean section 9 d after the expected date following the failure of oxytocin to induce labor (40 wk and 9 d, male, 3380 g, 8/10/NR) | Born healthy. Possible minor extrapyramidal manifestations 4 wk after delivery (or withdrawal symptoms from fluphenazine) that responded to diphenhydramine elixir. Apparently well-nourished, well-developed, and alert child at 24 months |
| 3 | O'Connor *et al*[38], 1981 | 22 | Case report, 1/1 | Schizophrenia | Fluphenazine decanoate(50 mg fortnightly from 14 to 24 wk /increased over three wk to this dose/, then 100 mg fortnightly from 24 wk to delivery); chlorpromazine (from 12th week of pregnancy to delivery) | Her suicidal behavior gradually abated after the LAI-AP dosage increase, but she continued to exhibit denial of pregnancy, extreme unpredictability, and total resistance to obstetric examination | Delivered by cesarean section after spontaneous onset of labor (39 wk, male, 3530 g, 10/10/NR) | Excellent condition at delivery. Initial progress was good. On the 21st d after birth, he developed many neurological signs (*e.g.,* excessive irritability, choreiform and dystonic movements involving mainly the upper limbs, jittery behavior, and hypertonicity) which persisted for 9 months and were mainly treated with diphenhydramine. The symptoms were consistent with LAI withdrawal effects. Follow-up at 15 months of age revealed no abnormalities |
| 4 | Collins and Comer[39], 2003 | 35 | Case report, 1/1 | Schizoaffective disorder | Haloperidol decanoate (200 mg/2 wk, throughout the pregnancy – last dose 3 wk before delivery); not specified | She had an acute psychotic episode before induced delivery | Induced vaginal delivery (full term, female, 3880 g, 9/9/NR) | At birth was noted to be “jittery”, then developed diarrhea and metabolic acidosis, and was transferred to NICU at 3rd d. She became increasingly irritable, and on day 8 had an episode of tonic-clonic movements in all extremities with tongue thrusting and torticollis (possible tardive dyskinesia or withdrawal dyskinesia). Tonic-clonic episodes continued up to the 14th d of life (successfully treated with clonazepam). On day 21, she was discharged to foster care with no tremulous movements noted |
| 5 | Janjić *et al*[40], 2013 | 35 at 1st pregnancy, 38 at 2nd pregnancy | Case report, 1/2 | Schizophrenia | Zuclopenthixol decanoate (in 1st pregnancyinitially400 mg/2 wk, then upon discovery of the pregnancy at 13 wks’ gestation dose was decreased to 200 mg/month and this dose was also used during entire 2nd pregnancy); not specified | Maternal psychiatric status during both pregnancies, after each delivery, and during the follow-up period was favorable (continued to be rated as “borderline mentally ill”), with no exacerbations | Delivery method not specified for both pregnancies.1st pregnancy/child: (39 wk, female, 3750 g, 9/NR/NR);2nd pregnancy/child: (40 wk, female, 3700 g, 9/NR/NR) | Both girls were healthy without obvious congenital malformations. The brain ultrasound of the first child revealed some clinically insignificant periventricular hyperechogenicity. Both had been normally developing 3.5 yr and 6 months after delivery |
| 6 | Ballester-Gracia *et al*[41], 2019 | 43 | Case report, 1/1 | Bipolar disorder | Aripiprazole LAI(400 mg/month for first 2-3 wk of pregnancy, then decreased to 300 mg/month, entire pregnancy); not specified (probably none) | No recurrence of her illness or significant mood fluctuations during pregnancy. Two days after hospital discharge after delivery, she came as an outpatient and was euthymic, so LAI-AP dose was increased to 400 mg/4 wk | Spontaneous vaginal delivery without complications (40 wk and 4 d, female, 3500 g, 9/10/10) | No congenital malformations at birth or development abnormalities at five months after delivery |
| 7 | Sole *et al*[49], 2020 | 30 | Conference abstract, 1/1 | Schizophrenia | Aripiprazole LAI(400 mg/28 d, entire pregnancy), not specified | No psychiatric complications due to pregnancy and puerperium were reported. No bounding disorder was detected | Delivered without obstetric complications (41 wk, female, 3465 g, 9/10/NR) | No neonatal complications |
| 8 | Fernández-Abascal *et al*[21], 2021 | 35 (table), 39 (text) | Case series, 1/1 | Paranoid schizophrenia | Aripiprazole LAI(400 mg/28 d from beginning of pregnancy to 8th week, 300 mg/28 d from 8th week until delivery); not specified | Throughout pregnancy, the patient remained psychopathologically stable, and treatment adherence was maintained | Uncomplicated eutocic/vaginal delivery (38 wk and 5 d, gender?/male in text; female in table/, 3300 g, 9/10/NR) | During the first 6 wk of follow-up postural plagiocephaly and hypertonia were noted, that finally were resolved with physiotherapy. He developed normally during a 3-yr follow-up |
| 9 | Fernández-Abascal *et al*[21], 2021 | 29 (table), 32 (text) | Case series, 1/1 | Schizophrenia, schizotypal personality disorder | Aripiprazole LAI(400 mg/28 d from beginning of pregnancy to 20th week, 300 mg/28 d from 20th week until delivery); not specified | Adherence was maintained throughout the pregnancy with psychopathological stability and good adherence. She had clinical worsening 3 months after delivery | Admitted to ED for spontaneous delivery – eutocic/vaginal delivery, right medial episiotomy (31 wk and 5 d, female, 1800 g, 10/10/NR) | Remained in an incubator for 1 month due to prematurity. No congenital malformations were observed at delivery or during the postpartum period. She developed normally during a 2-yr follow-up |
| 10 | Fernández-Abascal *et al*[21], 2021 | 35 (table), 36 (text) | Case series, 1/1 | Paranoid schizophrenia | Aripiprazole LAI(400 mg/28 d from beginning of pregnancy to 5th week, 300 mg/28 d from 5th week until delivery); not specified | Psychopathological stability and proper treatment adherence were maintained throughout the pregnancy | Eutocic/vaginal delivery (39 wk and 6 d, male, 3140 g, 9/10/NR) | No congenital malformations were observed at birth, and the postpartum period proceeded without relevant events. Normal development at 2 months |
| 11 | Fernández-Abascal *et al*[21], 2021 | 31 | Case series, 1/1 | Schizophrenia | Aripiprazole LAI(160 mg/28 d from beginning of pregnancy until delivery); occasional budesonide inhalation | Throughout the pregnancy, the patient remained psychopathologically stable, and treatment adherence was maintained | Uncomplicated eutocic/vaginal delivery (39 wk and 5 d, male, 3102 g, 10/10/NR) | Born healthy. In the 2-yr follow-up he remained in good health and developed normally |
| 12 | Fernández-Abascal *et al*[21], 2021 | 38 (table), 39 (text) | Case series, 1/1 | Schizophrenia | Aripiprazole LAI(300 mg/28 d from beginning of pregnancy until delivery); not specified | Throughout the pregnancy, she remained psychopathologically stable, and treatment adherence was maintained | Eutocic/vaginal delivery (39 wk, male, 2940 g, 8/10/NR) | Born healthy. In the 1-yr follow-up, he remained in good health and developed normally |
| 13 | Fernández-Abascal *et al*[21], 2021 | 30 | Case series, 1/1 | Schizophrenia | Aripiprazole LAI(400 mg/28 d from beginning of pregnancy to 8th week); when pregnancy was confirmed the prescription dose of benzodiazepines was adjusted downwards until they were withdrawn along 4 wk, levothyroxine | To ensure psychopathological stability and to detect warning signs of decompensation, the patient was closely monitored weekly during pregnancy (no worsening was reported) | Eutocic/vaginal delivery (40 wk, male, 3400 g, 9/10/NR) | Born healthy. He has been followed for 18 months, and no malformation, developmental abnormalities, or growth retardation were detected |
| 14 | Eleftheriou *et al*[33], 2023 | 38 | Case series, 1/1 | Bipolar or psychotic disorder (exact diagnosis not specified) | Aripiprazole LAI(400 mg/month, pregnancy started on LAI treatment, interruption of treatment at 23 wk); folic acid | Postpartum hospitalization for psychosis relapse | Cesarian section (31 wk, NR, 1995 g, 6/8/NR) | Down’s syndrome, fetal hydrops complicated by septic shock, massive anuria, and death in 10 d. This syndrome cannot be considered a drug-induced malformation |
| 15 | Eleftheriou *et al*[33], 2023 | 25 | Case series, 1/1 | Bipolar or psychotic disorder (exact diagnosis not specified) | Aripiprazole LAI(400 mg/month, pregnancy started on LAI treatment which was continued until delivery); folic acid | Postpartum hospitalization for psychosis relapse | Vaginal delivery (40 wk, female, 3300 g, 9/10/NR) | Live birth with no malformations. No adaptation disorders after delivery |
| 16 | Eleftheriou *et al*[33], 2023 | 31 | Case series, 1/1 | Bipolar or psychotic disorder (exact diagnosis not specified) | Aripiprazole LAI(200 mg/month, pregnancy started on LAI treatment, interruption of treatment at 14 wk); folic acid, haloperidol (first trimester) | No hospitalization for psychosis relapse | Spontaneous abortion (miscarriage) at 15th week | Not applicable |
| 17 | Eleftheriou *et al*[33], 2023 | 35 | Case series, 1/1 | Bipolar or psychotic disorder (exact diagnosis not specified) | Aripiprazole LAI(200 mg/month, pregnancy started on LAI treatment which was continued until delivery); folic acid, haloperidol (first trimester) | No hospitalization for psychosis relapse | Spontaneous abortion (miscarriage) at 9th week | Not applicable |
| 18 | Eleftheriou *et al*[33], 2023 | 34 | Case series, 1/1 | Bipolar or psychotic disorder (exact diagnosis not specified) | Aripiprazole LAI(200 mg/month, pregnancy started on LAI treatment which was continued until delivery); folic acid, carbamazepine (in first trimester, stopped at 10 wk) | Postpartum hospitalization for psychosis relapse | Cesarian section (40 wk, male, 2900 g, 9/10/NR) | Live birth with no malformations. No adaptation disorders after delivery |
| 19 | Eleftheriou *et al*[33], 2023 | 28 | Case series, 1/1 | Bipolar or psychotic disorder (exact diagnosis not specified) | Aripiprazole LAI(400 mg/month, pregnancy started on LAI treatment which was continued until delivery); folic acid, oral aripiprazole (in first trimester) | No hospitalization for psychosis relapse | Cesarian section (40 wk, female, 3140 g, 7/9/NR) | Live birth with no malformations. No adaptation disorders after delivery |
| 20 | Eleftheriou *et al*[33], 2023 | 43 | Case series, 1/1 | Bipolar or psychotic disorder (exact diagnosis not specified) | Aripiprazole LAI(400 mg/month, pregnancy started on LAI treatment which was continued until delivery); folic acid. | No hospitalization for psychosis relapse | Vaginal delivery (40 wk, male, 2300 g, 10/10/NR) | Live birth with no malformations. No adaptation disorders after delivery |
| 21 | Eleftheriou *et al*[33], 2023 | 31 | Case series, 1/1 | Bipolar or psychotic disorder (exact diagnosis not specified) | Aripiprazole LAI(400 mg/month, pregnancy started on LAI treatment which was continued until delivery); folic acid | No hospitalization for psychosis relapse | Vaginal delivery (40 wk, male, 3500 g, 8/10/NR) | Live birth with no malformations. No adaptation disorders after delivery |
| 22 | Eleftheriou *et al*[33], 2023 | 20 | Case series, 1/1 | Bipolar or psychotic disorder (exact diagnosis not specified) | Aripiprazole LAI(400 mg/month, pregnancy started on LAI treatment which was continued until delivery); folic acid, haloperidol (in first trimester) | Hospitalization for psychosis relapse after stillbirth | Stillbirth at 26th week | Not applicable |
| 23 | Eleftheriou *et al*[33], 2023 | 31 | Case series, 1/1 | Bipolar or psychotic disorder (exact diagnosis not specified) | Aripiprazole LAI(400 mg/month, pregnancy started on LAI treatment which was continued until delivery); folic acid, paroxetine (in first trimester) | No hospitalization for psychosis relapse | Vaginal delivery (38 wk, female, 3120 g, 9/10/NR) | Live birth with no malformations. No adaptation disorders after delivery |
| 24 | Manouilenko *et al*[42], 2018 | 35 | Case report, 1/1 | Psychosis | Olanzapine pamoate(405 mg/4 wk, from 25th week, reduced to 300mg/4 wk from 29th week and ultimately due to sedation to 210 mg/2 wk at 39th week, exposure until delivery); oral olanzapine for 4 d and promethazine injections before initiation of LAI-AP | Improved rapidly on LAI-AP, but she was hospitalized at pregnancy week 40 since she reported fatigue and depression | Vaginal delivery was induced by amniotomy (40 wk, female, 2930 g, 9/10/10) | Fully developed infant. The child’s somatic and psychomotor development up to 3 yr of age was normal |
| 25 | de Azevedo Avelar *et al*[43], 2020 | 26 | Case report, 1/1 | Schizophrenia | Paliperidone palmitate (263 mg every three months twice during pregnancy, the last one approximately 2 months before birth – exposure during entire pregnancy); none | She was doing well on this LAI-AP (asymptomatic on follow-up) | Presented to ED with abdominal pain, found to be in labor – pregnancy was not planned nor monitored (unknown gestational age, male, 2420 g, 9/10/10) | Approximately 1 yr after birth no health or developmental issues |
| 26 | Zamora Rodríguez *et al*[44], 2017 | 34 | Case report, 1/1 | Bipolar schizoaffective disorder | Paliperidone palmitate(100 mg/4 wk initially, then reduced to 50 mg/4 wk, she was pregnant for 2 wk when it was initiated, and dosage reduced at 5 wk of pregnancy and remained at this dosage until and after delivery); venlafaxine and clonazepam for first 5 wk, which were then changed to fluoxetine and lorazepam, omeprazole and yodocefol | No psychotic or affective symptoms except for a slight period of anxiety in the days immediately after discovering she was pregnant, and a mild and self-limited depressive relapse from days 7 to 9 after giving birth | Term birth, delivery mode not specified (40 wk, male, 2440 g, 9/10/10) | Clinical status of the newborn was normal. No diseases or malformations were detected in the first year of follow-up |
| 27 | Özdemir *et al*[45], 2015 | 37 | Case report, 1/1 | Schizophrenia | Paliperidone palmitate (100 mg monthly, from beginning until week 28 of gestation – last dose given at the 28th week); haloperidol orally from 29th week until delivery | Developed psychotic symptoms despite regular injections of LAI-AP 2 wk before a change to haloperidol was made (her symptoms subsided 3 wk afterwards) | Cesarean section without complications (39 wk, male, 3000 g, 9/NR/NR) | The baby has been followed for 4 months, and no malformation or growth retardation was detected |
| 28 | Binns *et al*[46], 2017 | 28 | Case report, 1/1 | Chronic paranoid schizophrenia | Paliperidone palmitate(150 mg/4 wk, entire pregnancy); not specified | Good control of psychosis was maintained | Pregnancy was complicated by polyhydramnios, induced labor followed by cesarean section due to fetal distress (39 wk, male, 3840 g, 9/9/NR) | Neonatal clinical examination confirmed a minor correctable congenital anomaly, bilateral talipes equinovarus, which was managed conservatively but was otherwise normal. The early postnatal course was uncomplicated |
| 29 | Iwata *et al*[34], 2021 | 30 | Case report, 1/1 | Schizophrenia | Paliperidone palmitate (150 mg/monthly, first dose was given at 34 wks' gestation, and she electively gave birth at 38 wks' gestation); initially from beginning of pregnancy olanzapine orally (problems with adherence) up to 32nd week, then risperidone orally for 7 d during 33rd week of pregnancy | Doing well on LAI-AP (after its initiation at the third trimester she had a notable improvement in positive and negative symptoms, and the delivery was performed without any issues) | Uneventful cesarean section (38 wk, male, NR, NR/NR/NR) | Transient tachypnea of the newborn that was managed with nasal continuous positive airway pressure. He was discharged 29 d after the delivery. Normal growth and neuropsychological development at 12 months after birth |
| 30 | Erdoğan *et al*[35], 2017 | 25 | Case report, 1/1 | Schizophrenia | Paliperidone palmitate (150 mg/monthly, from beginning of pregnancy, last dose given at 22nd week); not specified | She discontinued LAI-AP use without consultation with a clinician. At the 29th week of pregnancy, she was hospitalized with an acute psychotic attack | Normal vaginal delivery (40 wk, male, 3200 g, 9/10/NR) | Born healthy baby. Normal neurobehavioral development according to BSID-III (subscales of cognitive, motor, and language developments were in normal ranges at 2, 6, 12, 18, and 24 months of age) |
| 31 | Erdoğan *et al*[35], 2017 | 32 | Case report, 1/1 | Schizophrenia | Paliperidone palmitate(150 mg/monthly, entire pregnancy); not specified | No information about worsening of her condition during treatment. Four months after delivery she gave baby to ward of state | Normal vaginal delivery (41 wk, female, 2980 g, 9/10/NR) | Normal neurobehavioral development according to BSID-III (subscales of cognitive, motor and language developments were in normal ranges at 2, 6, 12, and 18 months of age) |
| 32 | Eleftheriou *et al*[33], 2023 | 26 | Case series, 1/1 | Bipolar or psychotic disorder (exact diagnosis not specified) | Paliperidone LAI (50 mg/month, pregnancy started on LAI treatment which was continued until delivery); folic acid, lorazepam (first trimester) | Postpartum hospitalization for psychosis relapse | Cesarian section (39 wk, female, 3020 g, 9/9/NR) | Live birth with no malformations. No adaptation disorders after delivery |
| 33 | Eleftheriou *et al*[33], 2023 | 32 | Case series, 1/1 | Bipolar or psychotic disorder (exact diagnosis not specified) | Paliperidone LAI (100 mg/month, pregnancy started on LAI treatment which was continued until delivery); folic acid | No hospitalization for psychosis relapse | Cesarian section (40 wk, male, 3250 g, 9/10/NR) | Live birth with no malformations. No adaptation disorders after delivery |
| 34 | Eleftheriou *et al*[33], 2023 | 30 | Case series, 1/1 | Bipolar or psychotic disorder (exact diagnosis not specified) | Paliperidone LAI(100 mg/month, pregnancy started on LAI treatment which was continued until delivery); folic acid | Postpartum hospitalization for psychosis relapse | Cesarian section (39 wk, male, 3650 g, 10/10/NR) | Live birth with no malformations. No adaptation disorders after delivery |
| 35 | Eleftheriou *et al*[33], 2023 | 25 | Case series, 1/1 | Bipolar or psychotic disorder (exact diagnosis not specified) | Paliperidone LAI(100 mg/month, pregnancy started on LAI treatment which was continued until delivery); folic acid | No hospitalization for psychosis relapse | Cesarian section (40 wk, female, 3255 g, 9/10/NR) | Live birth with no malformations. No adaptation disorders after delivery |
| 36 | Eleftheriou *et al*[33], 2023 | 33 | Case series, 1/1 | Bipolar or psychotic disorder (exact diagnosis not specified) | Paliperidone LAI(50 mg/month, pregnancy started on LAI treatment which was continued until delivery); folic acid, haloperidol (first trimester) | No hospitalization for psychosis relapse. | Cesarian section (39 wk, female, 3100 g, 9/10/NR). | Live birth with no malformations. No adaptation disorders after delivery. |
| 37 | Clinebell *et al*[47], 2017 | 32 | Case report, 1/1 | Bipolar disorder | Risperidone LAI (50 mg/2 wk, entire pregnancy); risperidone orally, citalopram, and benztropine (entire pregnancy) | She was doing well | Intrauterine growth restriction, and, due to concerns for placental insufficiency, she had induction of labor (35 wk, male, 2098 g, 8/8/9) | Born healthy, but with bilateral supernumerary nubs/digits on his hands that were removed after birth (this anomaly was a paternal family trait). The child has met developmental milestones at 16 months |
| 38 | Kim *et al*[48], 2007 | 35 | Case report, 1/1 | Schizophrenia | Risperidone LAI (25 mg/2 wk, entire pregnancy); not specified | Her psychotic symptoms improved markedly with LAI-AP treatment. No information about relapse | She delivered vaginally 3 h after premature rupture of membranes (36 wk and 6 d, female, 2230 g, 9/9/NR) | No evidence of congenital malformation at birth and no developmental abnormalities were found 8 months postnatally |
| 39 | Nguyen *et al*[20], 2022 | Mean±SD: All: 30.3±5.5;FGA: 31.0±6.0;SGA: 29.1±4.5 | Case series, 36/38 | Schizophrenia (25/69.4%);Schizoaffective disorder (6/16.7%);Bipolar affective disorder (3/8.3%);Unspecified psychosis (2/5.6%) | FGA (24/38): zuclopenthixol – 12 (100 mg fortnightly – 2, 150 mg fortnightly – 2, 200 mg fortnightly – 5, 200 mg monthly – 1, 300 mg fortnightly – 1, 300 mg monthly – 1); flupentixol – 9 (20 mg fortnightly – 1, 30 mg fortnightly – 1, 40 mg fortnightly – 5, 40 mg monthly – 1, 100 mg fortnightly – 1); fluphenazine – 2 (50 mg fortnightly); haloperidol – 1 (dose missing).SGA (14/38): aripiprazole – 8 (300 mg monthly – 1; 400 mg monthly – 7), risperidone – 4 (37.5 mg fortnightly – 1; 37.5 mg monthly – 1, 50 mg fortnightly – 2); paliperidone – 2 (100 mg monthly).First trimester exposure data only on 35/38 pregnancies, with 1/38 having a third trimester exposure and first trimester data were missing for 2/38. Nearly half (n = 17, 44.7%) were on LAI-AP as the sole medication while the rest had exposures to other oral medications including olanzapine, quetiapine, diazepam, chlorpromazine, risperidone, benztropine, venlafaxine, aripiprazole, fluoxetine, escitalopram, desvenlafaxine, lamotrigine) | Psychiatric relapse reported in 9 (40.9%) pregnancies in women on FGA and 3 (27.3%) pregnancies in women on SGA LAI-AP. Note: Valid% reported due to missing data | All pregnancies: spontaneous delivery in 13 (34.2%), emergency cesarean section in 11 (28.9%), premature birth (< 37 wk) in 6 (15.8%).Induction in 16 (66.7%) on FGA and 7 (50.0%) on SGA, emergency cesarean section in 8 (33.3%) on FGA and 3 (21.4%) on SGA, premature birth (< 37 wk) in 5 (20.8%) on FGA and 1 (7.1%) on SGA. Note: Valid% reported due to missing data. For all babies the mean gestational age was 38.25 wk (SD = 2.19) and mean birth weight was 3.18 kg (SD = 0.76). Gender and Apgar score were NR | Admission to a special care nursery was reported in a total of 18 *i.e.,* 47.4% of babies (13 *i.e.,* 54.2% and 5 *i.e.,* 35.7% whose mothers received FGA and SGA, respectively). Congenital malformations were recorded in 2 babies, and with data available on first-trimester exposure in only 35 pregnancies, this gives a 5.7% rate. One baby had undescended testes whose mother was treated with risperidone LAI, and the other was a patent ductus arteriosus in a baby of a woman who received flupentixol LAI. Both babies were managed conservatively. The authors were not able to assess for neonatal extrapyramidal syndrome (not recorded in their data) |

AP: Antipsychotic(s); BSID-III: Bayley Scales of Infant and Toddler Development 3rd Ed; ED: Emergency department; FGA: First-generation antipsychotics; LAI: Long-acting injectable; NICU: Neonatal intensive care unit; NR: Not reported; SD: Standard deviation; SGA: Second-generation antipsychotics.